CSBio CSBio

X
[{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Millmount Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsca\u00aeApproved in Japan for Additional Indication of Hyponatremia Due to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Tai Tien Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Canagliflozin (TA-7284) has Been Approved in Taiwan For Diabetic Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Akebia Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Therapeutics Receives Complete Response Letter from U.S. FDA for Vadadustat for the Treatment of Anemia associated with Chronic Kidney Disease in Adult Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Announces EC Approval Of Lupkynis\u00ae (Voclosporin) As First Oral Treatment For Active Lupus Nephritis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Peptide","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-CD20 Monoclonal Antibody Rituxan\u00ae Approved for Lupus Nephritis that has Not Responded Sufficiently to Existing Therapies","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Zenyaku Kogyo"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renalys Pharma is Launched to Bring New Innovative Medicines to Patients in Japan and Other Countries in Asia","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Renalys Pharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Filspari (sparsentan) is a once-daily oral medication is designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II). It isapproved for the treatment of IgA Nephropathy.

            Lead Product(s): Sparsentan

            Therapeutic Area: Nephrology Product Name: Filspari

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 25, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Rituxan (rituximab) is an anti-CD20 monoclonal antibody that specifically binds to CD20, a protein expressed on B cells, excluding hematopoietic stem cells and plasma cells, which is used for the treatment of Lupus Nephritis.

            Lead Product(s): Rituximab

            Therapeutic Area: Nephrology Product Name: Rituxan

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Chugai Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 23, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            EC approval is based on positive results, which demonstrated that treatment with voclosporin (lupkynis), in combination with MMF and low-dose corticosteroids, led to statistically superior complete renal response rates at 52 weeks compared to MMF and low-dose corticosteroids.

            Lead Product(s): Voclosporin

            Therapeutic Area: Nephrology Product Name: Lupkynis

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 20, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor under review for the treatment of anemia due to chronic kidney disease (CKD).

            Lead Product(s): Vadadustat

            Therapeutic Area: Nephrology Product Name: Vafseo

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Akebia Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 31, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Tai Tien Pharmaceuticals has obtained the regulatory approval of CANAGLU® (CANAGLU)(INN: canagliflozin; Japan names: CANAGLU® Tablets 100mg) for a treatment agent for diabetic nephropathy in Taiwan FDA.

            Lead Product(s): Canagliflozin

            Therapeutic Area: Nephrology Product Name: Canaglu

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Tai Tien Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 26, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Oral vasopressin V2-receptor antagonists Samsca® Tablets, Samsca® OD Tablets and SAMSCA® Granules 1% have received regulatory approval in Japan for the indication of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in adults.

            Lead Product(s): Tolvaptan

            Therapeutic Area: Nephrology Product Name: Samsca

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Millmount Healthcare

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 29, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY